Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
暂无分享,去创建一个
T. Hassanein | X. Forns | S. Zeuzem | D. Nelson | J. Kort | Y. Horsmans | Samuel S. Lee | F. Mensa | S. Lens | J. Valdes | R. Ghalib | R. Morillas | H. Hinrichsen | D. Rincón | F. Felizarta | P. Krishnan | Yao Yu | H. Aguilar | Chih‐Wei Lin | Preethi Krishnan
[1] Jean-Michel Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.
[2] J. Rockstroh,et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] P. Kwo,et al. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. , 2017, Gastroenterology.
[4] Liangjun Lu,et al. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir , 2017, Antimicrobial Agents and Chemotherapy.
[5] T. Asselah,et al. From HCV To HBV Cure , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[6] T. Hassanein,et al. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. , 2016, Gastroenterology.
[7] T. Asselah,et al. Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectives , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[8] T. Asselah,et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.
[9] T. Berg,et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. , 2015, The New England journal of medicine.
[10] Aasld Idsa Hcv Guidance Panel. Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.
[11] P. Marcellin,et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis , 2015, Hepatology.
[12] K. Reddy,et al. GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection , 2015, Annals of Internal Medicine.
[13] P. Klenerman,et al. Hepatitis C , 2015, The Lancet.
[14] H. Razavi,et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.
[15] A. Flaxman,et al. Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.
[16] C. Rice,et al. Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource , 2013, Hepatology.
[17] A. Flaxman,et al. Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.
[18] Edoardo Cervoni,et al. Hepatitis C , 1998, The Lancet.
[19] A. Bhalla,et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.
[20] D. Harnois,et al. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression , 2010 .